Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Mobile App For Reporting ADRs To Be Tested In Burkina Faso And Zambia

Executive Summary

An app for reporting adverse drug reactions developed by Europe’s Innovative Medicines Initiative is being tested in two African countries, where the mobile infrastructure is said to be more advanced than in EU. The app is expected to help in the collection of ADR data from malaria programs and from general medicines use.

You may also be interested in...



EU ADR app to underpin region's regulatory approach to social media

Europe is set to modernize how it conducts some aspects of pharmacovigilance with the launch of a web app in March this year for patients to report adverse drug reactions (ADRs) and a drive to monitor web chatter on the issue. Mick Foy, Group Manager Vigilance Intelligence at the UK’s Medicines and Healthcare products Regulatory Agency, has warned that without progress on the social-media front, manufacturers might shy away from the area to avoid a legal and ethical minefield.

Global Medtech Guidance Tracker: February 2021

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.

First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod

New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel